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Dense granule secretion 
A B S T R A C T   
PCTP (phosphatidylcholine transfer protein) was discovered recently to regulate aggregation of human platelets 
stimulated with PAR4 activating peptide (PAR4AP). However, the role of PCTP following thrombin stimulation, 
the mechanisms by which PCTP contributes to platelet activation, and the role of PCTP with other receptors 
remained unknown. As mouse platelets do not express PCTP, we treated human platelets with various agonists in 
the presence of the specific PCTP inhibitor A1. We observed that PCTP inhibition significantly reduced dense 
granule secretion in response to thrombin, PAR1AP, PAR4AP, convulxin (GPVI agonist) and FcγRIIA cross-
linking. In contrast, among these agonists, PCTP inhibition reduced aggregation only to low dose thrombin and 
PAR4AP. Unlike its effects on dense granule secretion, PCTP inhibition did not reduce alpha granule secretion in 
response to thrombin or PAR4AP. PCTP inhibition reduced both the increase in cytoplasmic Ca2+ as well as PKC 
activity downstream of thrombin. These data are consistent with PCTP contributing to secretion of dense 
granules, and to being particularly important to human PAR4 early signaling events. Future studies will address 
further these molecular mechanisms and consequences for hemostasis and thrombosis.   
1. Introduction 
The role of PCTP in platelet activation first came to attention when a 
team including one of us (LE) discovered that the level of PCTP protein 
correlated with platelet aggregation to PAR4AP [1]. The higher the 
PCTP level, the greater the reactivity to PAR4AP, at doses of 50 μM and 
75 μM. PCTP protein is absent in mouse platelets [1]. Therefore, in order 
to learn more about the role of PCTP, the investigators treated human 
platelets with a well characterized PCTP inhibitor, A1, prior to their 
being stimulated with either PAR1AP or PAR4AP. There was no effect of 
A1 on PAR1AP-mediated aggregation at A1 doses of 25, 50 and 100 μM. 
In contrast, A1 at 100 μM fully inhibited platelet aggregation to 
PAR4AP. Lower doses of A1 were either ineffective (25 μM) or partially 
effective (50 μM) in inhibiting PAR4AP stimulation. Thus, the A1 dose 
response and the role of PCTP in PAR4-mediated aggregation were 
established. However, thrombin is the physiologic agonist and works on 
both PAR1 and PAR4 on human platelets. Recognizing the different 
affinity of thrombin for PAR1 and PAR4 and the differences in signaling 
is critical to understanding the mechanisms of PARs in platelet activa-
tion and thrombosis. 
The role of PCTP in thrombin-mediated activation events including 
granule secretion and aggregation, the mechanisms by which it con-
tributes to platelet activation downstream of PAR4, and the role of PCTP 
with other agonists such as those stimulating ITAM-linked receptors, 
remains unknown. 
In this work, we have studied the role of PCTP in thrombin stimu-
lation of dense granule secretion, aggregation and alpha granule secre-
tion. We compared the effects of PCTP inhibition on thrombin 
stimulation with that of PAR4AP, PAR1AP and agonists of ITAM-linked 
(immunoreceptor tyrosine-based activation motif) receptors GPVI and 
FcγRIIA. We report for the first time that PCTP inhibition in human 
platelets reduces dense granule secretion by blunting the increase in 
intracellular Ca2+ and decreasing PKC activity. 
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2. Materials and methods 
2.1. Reagents 
PCTP inhibitor-A1 was purchased from Tocris Bioscience (Minne-
apolis, MN, USA) and dimethyl sulfoxide (DMSO) from Sigma (St. Louis, 
MO, USA). PAR1AP and PAR4AP from GL-Biochem (China), Human 
alpha thrombin from Enzyme Research laboratories (South Bend, IN, 
USA) and PGE1 from Cayman Chemicals (Ann Arbor, MI, USA). Chrono- 
lume and ATP were from Chrono-log (Havertown, PA, USA). Anti- 
CD62P-PE was purchased from eBiosciences/Thermo Fisher Scientific 
(Waltham, MA, USA). Acid citrate dextrose (ACD) tubes were obtained 
from BD (Franklin Lakes, NJ, USA). BCA kit and 5× reducing gel loading 
buffer from Pierce/Thermo Fisher Scientific. Protease inhibitor cocktail 
tablets and Phosphatase inhibitor cocktail tablets were purchased from 
Roche Diagnostics (Indianapolis, IN, USA), sodium fluoride, sodium 
orthovanadate and PMSF from Sigma/Thermo Fisher Scientific. Phos-
pho PKC substrate and p-PKD2 antibodies were purchased from Cell 
Signaling Technology (Danvers, MA, USA) and GAPDH antibody from 
Proteintech (Rosemont, IL, USA). Goat anti-rabbit and Goat anti-mouse 
antibodies were obtained from LICOR (LI-COR Biosciences, Lincoln, 
Nebraska). Calcium 6 QF assay kit, 96-well black, clear-bottom plate, 
and 96-well black pipette tips for Flex station were purchased from 
Molecular Devices, (San Jose, CA, USA). Convulxin was obtained from K 
J Clemetson (Theodor Kocher Institute, University of Berne, 
Switzerland), IV.3 antibody from Stemcell Technologies, (Vancouver, 
Canada), and goat anti-mouse Antibody (GAM) from Jackson Immu-
noresearch labs, (Westgrove, PA). Qiagen Blood Core Kit was purchased 
from Qiagen (Germantown, MD, USA). PAR4 primers were synthesized 
by Eurofins (Horsham, PA, USA), as follows: forward primer 5′
AAGTCTGTGCCAATGACAGT 3′, reverse primer 5′ GCTCGGGTCCGAG-
TAATG 3′. 
All other chemicals were purchased from Sigma or Fisher Scientific. 
2.2. Preparation of washed human platelets 
Healthy volunteers were recruited according to the protocols 
approved by the Institutional Review Board at Thomas Jefferson Uni-
versity, Philadelphia, PA. Informed consent forms were signed prior to 
blood draw. Venous blood from each volunteer was drawn into vacu-
tainer tubes containing ACD and washed platelet suspensions were 
prepared as follows. Briefly, whole blood was centrifuged at 800 rpm for 
20 min with no brakes and the platelet rich plasma (PRP) separated. PRP 
was diluted with HEN buffer (10 mM HEPES, 150 mM sodium chloride 
and 1 mM EDTA, pH 6.5) at a ratio 4:1 and 1 μM PGE1 was added to the 
PRP. Platelet pellet was obtained following centrifugation at 1300 rpm 
for 10 min. Platelets were resuspended in modified Tyrode’s buffer (137 
mM NaCl, 25 mM HEPES, 1 mM MgCl2, 2.7 mM KCl, 0.1% Glucose, 
0.485 mM NaH2PO4, 12 mM NaHCO3, 1 mM CaCl2, pH 7.4) to a final 
concentration of 3 × 108/ml or as indicated below. After final resus-
pension, the platelets were rested at 37 ◦C for 30 min before use in 
experiments. 
2.3. Genotyping of PAR4 single nucleotide variant (SNV) rs773902 (G/ 
A; Ala/Thr120) 
We used whole blood obtained in ACD tubes, then centrifuged at 
250g for 15 min with no brake. The buffy coat layer was isolated and 
genomic DNA (gDNA) was extracted via the Blood core kit. The gDNA 
was amplified with PAR-4 specific primers surrounding the SNV, and the 
sequence of the PCR product was obtained. All of the 5 donors in this 
study, 4 Caucasians and 1 Asian, were homozygous for rs773902 GG 
(Ala120/Ala120). Recent studies have indicated that the PAR4 SNV 
contributes to differential response of human platelets at thrombin doses 
≤0.8 nM and PAR4AP doses ≤75 μM [2–4]. In this report, we used 
thrombin at ≥1 nM and PAR4AP at ≥100 μM, so there was no expected 
contribution of the SNV genotype. 
2.4. Platelet treatment with inhibitor A1 
Washed human platelets were pre-incubated with PCTP inhibitor A1 
at 100 μM for 1 h at 37 ◦C. Control platelets were in the same buffer 
(modified Tyrode’s buffer and final concentration 0.5% DMSO) but 
received no inhibitor. Platelets were then stimulated with agonists 
thrombin, PAR1AP, PAR4AP, convulxin or IV.3 + GAM at concentra-
tions indicated in each experiment. We used A1 at 100 μM because 
published dose response studies identified that dose as the minimum 
effective concentration in inhibiting human platelet aggregation [1]. 
2.5. Platelet dense granule secretion and aggregation 
For this assay, 3 × 108 cells/ml were stimulated with agonists 
following pre-treatment of platelets in a Chronolog lumi-aggregometer 
(Chronolog-Log Corporation, Havertown, PA) at 37 ◦C under stirring 
conditions (1200 rpm). Agonists and concentrations employed were as 
follows: thrombin at 1 nM and 2 nM, PAR1AP at 1 μM and 10 μM, 
PAR4AP at 100 μM and 200 μM, convulxin at 50, 100 and 200 ng/ml, 
and IV.3 + GAM at (1 + 5) or (2 + 10) μg/ml. For FcγRIIA stimulation 
and its known inter individual variability [5], the concentration of the 
ligand used was 1 + 5 μg/ml (n = 3) or 2 + 10 μg/ml (n = 2) based on 
our criterion that we obtain at least 50% aggregation in the no inhibitor 
control. 
Platelet dense granule secretion was measured as release of ATP on 
agonist stimulation. Briefly, 5 μl of Luciferin/Luciferase reagent-Chrono- 
lume was resuspended per manufacturer’s instructions and added to 
245 μl of pre-treated platelets for 2 min before stimulation with agonists. 
The ATP-Luciferin-Luciferase reaction was standardized with 2 nmole of 
ATP. 
2.6. Flow cytometry for P-Selectin expression 
Washed human platelets resuspended in Tyrode’s buffer with 1 mM 
CaCl2 were incubated with A1 or no inhibitor control as described 
earlier. For P-selectin expression, the cells (50 μl) were stimulated with 
agonists for 10 min at 37 ◦C and subsequently incubated with 2 μl of PE 
conjugated anti-CD62P (1:5 dilution) for another 10 min. The samples 
were fixed by the addition of 450 μl of Tyrode’s buffer containing 1% 
PFA and 0.1% BSA. Samples were analyzed on a BD Accuri C6 flow 
cytometer (BD Biosciences, San Jose, CA, USA) and the data processed 
using BD Accuri C6 software. 
2.7. Intracellular Ca2+ flux assay 
Washed human platelets (3 × 108 cells/ml) were pre-incubated with 
A1 inhibitor vs control at 37 ◦C for 1 h, assessed for changes in cytosolic 
Ca2+ concentrations upon agonist stimulation using a Ca2+ sensitive 
fluorescent dye. The manufacturer’s instructions for preparing the dye 
loading buffer and flex station 3 plate reader were followed. Briefly, 
platelets were preincubated with 100 μM A1 vs. no inhibitor control for 
30 min at 37 ◦C, then an equal volume of FLIPR Calcium 6 QF loading 
dye added, and incubation continued for 20 min at 37 ◦C in the dark. 
Platelets in buffer with Ca2+ at 2 mM final concentration were seeded 
onto a 96-well, black clear bottom plate (180ul/well), and incubation 
continued for another 10 min at 37 ◦C in the Flex station 3 plate reader 
(Molecular Devices). The total incubation time following dye addition 
was 30 min. At 10× concentration, the agonist was added to a 96-well 
plate and loaded to the Flex station 3. Fluorescence readings were 
recorded with excitation at 485 nm, emission at 525 nm, and automatic 
emission cut off at 515 nm. The platelet samples were analyzed in Flex 
Station 3, baseline fluorescence measured (60s) prior to the addition of 
the agonist (20 μl/well) robotically, and fluorescence signal recorded for 
additional 4 min following agonist stimulation. Relative Ca2+
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Fluorescence values were quantified as fold change, the ratio of the peak 
magnitude signal to the basal signal in each well. 
2.8. Immunoblotting 
Total protein lysates from human (3 × 108/ml) platelets were ob-
tained by addition of 1× RIPA buffer (150 mM NaCl, 1% NP 40, 0.5% Na 
deoxycholate, 0.1% SDS, 50 mM Tris pH 8.0 and 1 mM EGTA) with 
protease inhibitors (PMSF, NaF, Na vanadate, protease inhibitor cock-
tail, phosphatase inhibitor cocktail) following stimulation of A1 treated 
platelets with 1 nM thrombin for time points − 1, 3 and 5 min. The ly-
sates were kept on ice for 20 min and stored at − 80 ◦C until use. Protein 
concentration of the cell lysates were measured by BCA Kit. Equal 
amount of protein (30 μg) was loaded in each lane with gel loading 
buffer (5×) containing 100 mM DTT. Prior to loading, the lysates were 
heated at 100 ◦C for 10 min. 
For immunoblotting, cell lysates were fractionated onto a 10% SDS- 
PAGE, then transferred to a nitrocellulose membrane, blocked with TBS 
containing 3% BSA for 30 min to 1 h at room temperature (RT). The 
blots were probed with p-PKC substrate antibody (1:500) or p-PKD2 
antibody (1:250) incubated overnight at 4 ◦C. The proteins were 
detected with a goat anti-rabbit secondary antibody (1:15,000; LICOR) 
which was incubated at RT for 1 h. The immunoblots were imaged by 
LICOR Odyssey system and analyzed using LICOR image Lite Software 
ver. 5.2 (LI-COR Biosciences, Lincoln, NE). Membranes were then 
stripped with stripping buffer (25 mM glycine-pH 2.5, 1% SDS) and 
analyzed for equal loading of protein with GAPDH antibody, as primary 
antibody, followed by goat anti-mouse (1: 15,000), as secondary 
antibody. 
Fig. 1. PCTP regulates dense granule secretion to multiple agonists and aggregation to thrombin. ATP release was assessed in washed human platelets (3 × 108 cells/ 
ml) treated with PCTP inhibitor A1 (100 μM) vs no inhibitor control before stimulation with thrombin, PAR1-AP, or PAR4-AP (A) and convulxin or FcγRIIA receptor 
ligand (IV.3 + GAM; see Materials and methods for dose) agonists at the concentrations indicated (C). A1 reduced ATP secretion for all agonists tested (mean of each 
condition shown by horizontal line, p < 0.05). Maximum aggregation to thrombin, PAR1AP or PAR4AP (B) and convulxin or IV.3 + GAM (D) showed significant 
reduction by A1 with thrombin stimulation. Two-way ANOVA was used to assess statistical significance with Bonferroni post-hoc tests for (B) and (D); One sample t- 
test was used for (A) and (C), and p-values <0.05 were considered significant. *p < 0.05, **p < 0.01, ***p < 0.001. 
Fig. 2. PCTP inhibitor A1 does not inhibit alpha granule release to thrombin or PAR4AP. Alpha granule secretion was determined in washed human platelets (6 ×
10^7 cells/ml) treated with A1 (100 μM) or vehicle followed by stimulation with thrombin or PAR4AP at concentrations indicated. P-Selectin expression was assessed 
with CD62-PE antibody by flow cytometry on Accuri C6. (A) The bar graph represents P-selectin positive cells (n = 4). (B) A representative flow cytometry data. Two- 
way ANOVA with Bonferroni post-hoc test detected no statistical significance, and p-value <0.05 considered as significant. 
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2.9. Statistical analysis 
Data analysis was performed using PRISM v5 (GraphPad, CA). All 
data are expressed as mean ± SEM as indicated in each figure legend. 
The statistical significance was calculated using two-way ANOVA, Stu-
dent’s t-test or one sample t-test as indicated in each figure legend; p <
0.05 was considered statistically significant. 
3. Results 
3.1. PCTP regulates dense granule secretion by multiple agonists 
Dense granule secretion was inhibited by PCTP inhibitor A1 in 
platelets stimulated by thrombin at doses of 1 and 2 nM (Fig. 1A, p <
0.05). A1 also inhibited dense granule secretion by PAR1AP, PAR4AP, 
convulxin (GPVI agonist) and IV.3 + GAM (Fig. 1A and C, p < 0.05). The 
trend with PAR1AP at 1 μM (mean reduction to 28% of no inhibitor 
control) did not reach statistical significance, but the difference was 
significant at 10 μM. These observations reveal a role for PCTP in dense 
Fig. 3. PCTP regulates the Ca2+ response stimulated by thrombin and PAR4. Ca2+ mobilization in washed platelets (3 × 108 cells/ml) treated with A1 (100 μM) vs. 
no inhibitor control was measured in response to the agonists indicated using a calcium 6 QF assay. Fluorescence data are presented as relative calcium fluorescence 
(FL) detecting fold change in cytosolic calcium (A–F); the graphs represent mean ± SEM from n = 5 independent experiments performed in technical duplicates. The 
bar graph (G) represents peak relative calcium fluorescence with mean ± SEM for the agonists examined. Unpaired Student’s t-test indicates statistical significance (p 
< 0.05) between control and A1-treated platelets. 
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granule secretion not only downstream of GPCRs (G-protein coupled 
receptors) PAR4 and PAR1 but also ITAM-linked receptors GPVI and 
FcγRIIA. 
3.2. PCTP regulates aggregation by thrombin 
A1 significantly inhibited aggregation upon stimulation with 1 nM or 
2 nM thrombin (Fig. 1B; p < 0.05). The degree of inhibition was less at 2 
nM thrombin than 1 nM thrombin. However, neither aggregation by 
PAR1-AP (1 μM and 10 μM) nor by higher doses of PAR4-AP (100 μM 
and 200 μM) were inhibited (Fig. 1B). Note that inhibition of aggrega-
tion by A1 (100 μM) was previously reported by Edelstein et al. when 
PAR4AP doses were lower, namely 50 and 75 μM [1]. 
A1 did not inhibit aggregation by convulxin or IV.3 + GAM, either 
(Fig. 1D). These findings indicate that PCTP regulates aggregation 
particularly at low to intermediate doses of thrombin and lower doses of 
PAR4AP. 
3.3. PCTP does not regulate alpha granule secretion 
We next investigated PCTP in alpha granule secretion using P- 
Selectin expression as a marker for release of alpha granule content. As 
shown in Fig. 2, the agonist-stimulated increase in P-selectin expression 
on the surface of platelets was the same in the presence or absence of 
PCTP inhibitor following stimulation with thrombin at 1 nM or 2 nM, as 
well as with PAR4-AP at 100 μM or 200 μM (n = 4; p not significant). 
Together, these observations are consistent with PCTP having a 
special role in dense granule secretion for these agonists at these doses. 
3.4. PCTP regulates the increase in intracellular Ca2+ in response to 
thrombin and PAR4AP 
Previous studies reported a decrease in Ca2+ mobilization in 
megakaryocyte-like Meg-01 cells treated with siRNA against PCTP prior 
to PAR4AP stimulation [1]. In that system, siRNA to PCTP did not affect 
the increase in intracellular Ca2+ following stimulation by PAR1AP. We 
evaluated the consequences for Ca2+ mobilization in A1- treated plate-
lets. In comparison with controls, A1 reduced the increase in Ca2+
significantly following stimulation with thrombin at 1 nM and PAR4AP 
at 100 μM (Fig. 3). In contrast, A1 did not inhibit the increase in Ca2+ in 
response to higher doses of thrombin at 2 nM or PAR4AP at 200 μM 
(Fig. 3). In addition, consistent with the findings in Meg-01 cells, A1 
inhibition did not affect the increase in intracellular Ca2+ in response to 
PAR1AP at 1 or 10 μM in human platelets . 
3.5. PCTP regulates phosphorylation of PKC substrates implicated in 
dense granule secretion 
Thrombin and PAR4 stimulation of human platelets regulate dense 
granule release via PKC [6–8]. We assessed phosphorylation of PKC 
substrates pleckstrin and PKD2 in platelets stimulated with thrombin at 
1 nM (Fig. 4A and C). Compared to controls, a statistically significant 
decrease in both pleckstrin and PKD2 phosphorylation was observed at 
1 min and 3 min in A1-treated platelets (Fig. 4B and D, p < 0.05). 
Together with the Ca2+ results, these findings are consistent with a role 
for PCTP in proximal PAR4 signaling. 
4. Discussion 
PCTP was first identified as contributing to the regulation of human 
platelet aggregation via PAR4 stimulated by PAR4AP [1]. Specifically, 
Fig. 4. PCTP regulates phosphorylation of PKC substrates Pleckstrin and Protein Kinase D2. Washed human platelets (3 × 108 cells/ml) were pre-incubated with 
PCTP inhibitor A1 (100 μM) vs. no inhibitor control for 1 h before stimulation with 1 nM thrombin. Cells lysed in RIPA buffer were fractionated on a 10% SDS-PAGE 
gel and immunoblotted with antibodies for PKC substrate (phospho-Pleckstrin) (A–B) and phospho-Protein Kinase D2 (pSer744/748) (C–D). The dot plots (B) and (D) 
depict the relative phosphoprotein level for the indicated time points following thrombin stimulation. Relative phosphoprotein levels were calculated as follows. 
First, each phosphoprotein band intensity was normalized for loading by the GAPDH band in its lane. Then, the ratio of the normalized phosphoprotein band intensity 
for A1-treated platelets to the normalized band intensity of control platelets at that same time point for that donor was computed. Those values are plotted, such that 
the respective untreated control for each time point has been set to 1. The mean is indicated by the horizontal line, with n = 6 independent experiments. Statistical 
significance analyzed by One sample t-test for each time point for p-values <0.05 (*), <0.01 (**), <0.001 (***). 
S. Abraham et al.                                                                                                                                                                                                                               
Thrombosis Research 202 (2021) 67–73
72
the level of PCTP protein correlated positively with aggregation to 
PAR4AP at doses of 50 and 75 μM. In contrast to the prior report of A1 
inhibition at low dose PAR4AP, we now show that aggregation is not 
inhibited at higher doses of PAR4AP, 100 and 200 μM. In order to 
identify the role of PCTP in response to the physiologic agonist 
thrombin, we treated human platelets with A1 and observed reduced 
dense granule secretion at thrombin doses of 1 and 2 nM. We then 
examined the effects of PCTP inhibition on dense granule secretion 
downstream of PAR1, GPVI and FcγRIIA. PCTP inhibition reduced dense 
granule secretion in response to agonists of each of these receptors, 
consistent with a more general role in this response. 
We observed that aggregation was inhibited by A1 both with low 
dose PAR4AP [Edelstein 2013] and thrombin. In contrast, PCTP inhi-
bition did not result in decreased aggregation in response to PAR1, GPVI 
or FcγRIIA stimulation. Recent work by a team (including LE and SMcK) 
demonstrated that aggregation is at maximal response at these doses and 
that PAR4 contributes significantly [2]. This point is important, since 
thrombin acts on both PAR1 and PAR4, but the major role of PCTP tracks 
with its effects on PAR4. Our findings are in keeping with the require-
ment for ADP secretion downstream of PAR4, acting via P2Y12 to sus-
tain aggregation to low dose thrombin [9–11]. Our model for PCTP 
action in stimulation of human platelets via PAR4 is depicted in Fig. 5. 
One outstanding question is, what is PCTP doing in the platelet 
response to agonists? PCTP has a canonical function in transferring PC 
(phosphatidylcholine) from the endoplasmic reticulum to the plasma 
membrane and other intracellular phospholipid membranes, often at 
specific membrane contact points [12]. PCTP is also a cofactor for the 
acyl CoA thioesterase ACOT13 [13]. Acyl CoA thioesterases release 
longer chain fatty acids from CoA, where they can serve in intermediary 
metabolism or in dynamic phospholipid remodeling. A1 blocks docking 
of PC to PCTP, interfering with both its PC transfer function and with its 
cofactor activity for ACOT13 [13]. Future studies are needed to see if 
one or both of these functions of PCTP are responsible for its role in 
platelet activation (Fig. 5). 
A second outstanding question is, how can PCTP function in both 
GPCR and ITAM pathways? PCTP actions in platelets are consistent with 
roles in the activity of both PLCβ, downstream of Gq-coupled GPCRs 
such as PAR4 and PAR1, and PLCγ2, downstream of ITAM receptors 
such as GPVI and FcγRIIA. In each case PCTP potentially facilitates 
generation of Inositol 3,4,5 phosphate (IP3) and diacyl glycerol (DAG) 
from phosphoinositol 4,5, bis phosphate (PI4,5,P2) to cause increased 
intracellular Ca2+ and PKC activity. PKC is a known regulator of dense 
granule secretion, consistent with our findings [9,11]. In this study, 
downstream of PAR4, PCTP inhibition reduced dense granule but not 
alpha granule secretion. Several groups have identified that dense 
granule secretion, but not alpha granule secretion, is regulated by PKC 
and PKD2 [7,8]. Phospho-PKC and -PKD2 likely function in dense 
granule secretion by phosphorylation of v-SNAREs, t-SNAREs and 
associated proteins such as SNAP23 and syntaxin-11 [14]. Future studies 
will be needed to explore how PCTP contributes to this difference. 
In conclusion, future studies of this newly recognized role for PCTP 
in human platelets will enable greater insights into its role in hemostasis 
and thrombosis. 
Fig. 5. Model of PCTP in human platelet PAR4 signaling. 
Downstream of Gq-coupled PAR4, PCTP supports the increase in intracellular Ca2+ and phosphorylation of PKC substrates Pleckstrin and PKD2. Together they 
regulate dense granule release, providing ADP to signal to P2Y12 (not shown) for sustained aggregation. 
S. Abraham et al.                                                                                                                                                                                                                               
Thrombosis Research 202 (2021) 67–73
73
CRediT authorship contribution statement 
S Abraham performed experiments, analyzed data, and wrote and 
edited the manuscript. LM, XK and S Askari performed experiments and 
edited the manuscript. LE conceived the project, reviewed data and 
edited the manuscript. SMcK conceived the project, analyzed data, and 
wrote and edited the manuscript. 
Declaration of competing interest 
The authors declare that they have no known competing financial 
interests or personal relationships that could have appeared to influence 
the work reported in this paper. 
This work was supported by the Cardeza Foundation for Hemato-
logical Research, USA. 
References 
[1] L.C. Edelstein, L.M. Simon, R.T. Montoya, M. Holinstat, E.S. Chen, A. Bergeron, et 
al., Racial differences in human platelet PAR4 reactivity reflect expression of PCTP 
and miR-376c, Nat. Med. 19 (12) (2013) 1609–1616. 
[2] M.J. Whitley, D.M. Henke, A. Ghazi, M. Nieman, M. Stoller, L.M. Simon, et al., The 
protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to 
low-dose thrombin and protease-activated receptor 4 desensitization, and is 
blocked by non-competitive P2Y12 inhibition, J. Thromb. Haemost. 16 (12) (2018) 
2501–2514. 
[3] S.L. French, C. Thalmann, P.F. Bray, L.E. Macdonald, A.J. Murphy, M.W. Sleeman, 
et al., A function-blocking PAR4 antibody is markedly antithrombotic in the face of 
a hyperreactive PAR4 variant, Blood advances. 2 (11) (2018) 1283–1293. 
[4] Y. Morikawa, H. Kato, H. Kashiwagi, N. Nishiura, K. Akuta, S. Honda, et al., 
Protease-activated receptor-4 (PAR4) variant influences on platelet reactivity 
induced by PAR4-activating peptide through altered Ca(2+) mobilization and ERK 
phosphorylation in healthy Japanese subjects, Thromb. Res. 162 (2017) 44–52. 
[5] Y. Zhou, S. Abraham, P. Andre, L.C. Edelstein, C.A. Shaw, C.A. Dangelmaier, et al., 
Anti-miR-148a regulates platelet FcgammaRIIA signaling and decreases thrombosis 
in vivo in mice, Blood. 126 (26) (2015) 2871–2881. 
[6] O. Konopatskaya, K. Gilio, M.T. Harper, Y. Zhao, J.M. Cosemans, Z.A. Karim, et al., 
PKCalpha regulates platelet granule secretion and thrombus formation in mice, 
J. Clin. Invest. 119 (2) (2009) 399–407. 
[7] O. Konopatskaya, S.A. Matthews, M.T. Harper, K. Gilio, J.M. Cosemans, C. 
M. Williams, et al., Protein kinase C mediates platelet secretion and thrombus 
formation through protein kinase D2, Blood. 118 (2) (2011) 416–424. 
[8] D. Bhavanasi, S. Kim, L.E. Goldfinger, S.P. Kunapuli, Protein kinase Cdelta 
mediates the activation of protein kinase D2 in platelets, Biochem. Pharmacol. 82 
(7) (2011) 720–727. 
[9] S. Kim, C. Foster, A. Lecchi, T.M. Quinton, D.M. Prosser, J. Jin, et al., Protease- 
activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence 
of secreted ADP and cause human platelet aggregation independently of G(i) 
signaling, Blood. 99 (10) (2002) 3629–3636. 
[10] L. Stefanini, D.S. Paul, R.F. Robledo, E.R. Chan, T.M. Getz, R.A. Campbell, et al., 
RASA3 is a critical inhibitor of RAP1-dependent platelet activation, J. Clin. Invest. 
125 (4) (2015) 1419–1432. 
[11] L. Stefanini, W. Bergmeier, Negative regulators of platelet activation and adhesion, 
J. Thromb. Haemost. 16 (2) (2018) 220–230. 
[12] S. Cockcroft, P. Raghu, Phospholipid transport protein function at organelle 
contact sites, Curr. Opin. Cell Biol. 53 (2018) 52–60. 
[13] N. Wagle, J. Xian, E.Y. Shishova, J. Wei, M.A. Glicksman, G.D. Cuny, et al., Small- 
molecule inhibitors of phosphatidylcholine transfer protein/StarD2 identified by 
high-throughput screening, Anal. Biochem. 383 (1) (2008) 85–92. 
[14] S. Joshi, S.W. Whiteheart, The nuts and bolts of the platelet release reaction, 
Platelets. 28 (2) (2017) 129–137. 
S. Abraham et al.                                                                                                                                                                                                                               
